נגישות
menu      
Advanced Search
Syntax
Search...
Volcani treasures
About
Terms of use
Manage
Community:
אסיף מאגר המחקר החקלאי
Powered by ClearMash Solutions Ltd -
Functional resolution of fibrosis in mdx mouse dystrophic heart and skeletal muscle by halofuginone
Year:
2008
Authors :
Pines, Mark
;
.
Volume :
294
Co-Authors:
Huebner, K.D., Department of Human Anatomy and Cell Science, Faculty of Medicine, University of Manitoba, MB, Canada
Jassal, D.S., Cardiac Sciences Department, Institute of Cardiovascular Sciences, University of Manitoba, MB, Canada
Halevy, O., Department of Animal Sciences, Faculty of Agriculture, Hebrew University of Jerusalem, Rehovot, Israel
Pines, M., Institute of Animal Sciences, Volcani Center, Bet-Dagan, Israel
Anderson, J.E., Department of Human Anatomy and Cell Science, Faculty of Medicine, University of Manitoba, MB, Canada, Department of Biological Sciences, Faculty of Science, University of Manitoba, MB, Canada, Dept. of Biological Sciences, Faculty of Science, Univ. of Manitoba, Dysart Rd., Winnipeg, MB R3T 2N2, Canada
Facilitators :
From page:
To page:
(
Total pages:
1
)
Abstract:
The effect of halofuginone (Halo) on established fibrosis in older mdx dystrophic muscle was investigated. Mice (8 to 9 mo) treated with Halo (or saline in controls) for 5, 10, or 12 wk were assessed weekly for grip strength and voluntary running. Echocardiography was performed at 0, 5, and 10 wk. Respiratory function and exercise-induced muscle damage were tested. Heart, quadriceps, diaphragm, and tibialis anterior muscles were collected to study fibrosis, collagen I and III expression, collagen content using a novel collagenase-digestion method, and cell proliferation. Hepatocyte growth factor and α-smooth muscle actin proteins were assayed in quadriceps. Halo decreased fibrosis (diaphragm and quadriceps), collagen I and III expression, collagen protein, and smooth muscle actin content after 10 wk treatment. Muscle-cell proliferation increased at 5 wk, and hepatocyte growth factor increased by 10 wk treatment. Halo markedly improved both cardiac and respiratory function and reduced damage and improved recovery from exercise. The overall impact of established dystrophy and dysfunction in cardiac and skeletal muscles was reduced by Halo treatment. Marked improvements in vital-organ functions implicate Halo as a strong candidate drug to reduce morbidity and mortality in Duchenne muscular dystrophy. Copyright © 2008 the American Physiological Society.
Note:
Related Files :
animal experiment
Animals
animal tissue
Cell Proliferation
Gene
mdx gene
mice
Muscular dystrophy
Show More
Related Content
More details
DOI :
10.1152/ajpheart.01253.2007
Article number:
Affiliations:
Database:
Scopus
Publication Type:
article
;
.
Language:
English
Editors' remarks:
ID:
21381
Last updated date:
02/03/2022 17:27
Creation date:
16/04/2018 23:43
You may also be interested in
Scientific Publication
Functional resolution of fibrosis in mdx mouse dystrophic heart and skeletal muscle by halofuginone
294
Huebner, K.D., Department of Human Anatomy and Cell Science, Faculty of Medicine, University of Manitoba, MB, Canada
Jassal, D.S., Cardiac Sciences Department, Institute of Cardiovascular Sciences, University of Manitoba, MB, Canada
Halevy, O., Department of Animal Sciences, Faculty of Agriculture, Hebrew University of Jerusalem, Rehovot, Israel
Pines, M., Institute of Animal Sciences, Volcani Center, Bet-Dagan, Israel
Anderson, J.E., Department of Human Anatomy and Cell Science, Faculty of Medicine, University of Manitoba, MB, Canada, Department of Biological Sciences, Faculty of Science, University of Manitoba, MB, Canada, Dept. of Biological Sciences, Faculty of Science, Univ. of Manitoba, Dysart Rd., Winnipeg, MB R3T 2N2, Canada
Functional resolution of fibrosis in mdx mouse dystrophic heart and skeletal muscle by halofuginone
The effect of halofuginone (Halo) on established fibrosis in older mdx dystrophic muscle was investigated. Mice (8 to 9 mo) treated with Halo (or saline in controls) for 5, 10, or 12 wk were assessed weekly for grip strength and voluntary running. Echocardiography was performed at 0, 5, and 10 wk. Respiratory function and exercise-induced muscle damage were tested. Heart, quadriceps, diaphragm, and tibialis anterior muscles were collected to study fibrosis, collagen I and III expression, collagen content using a novel collagenase-digestion method, and cell proliferation. Hepatocyte growth factor and α-smooth muscle actin proteins were assayed in quadriceps. Halo decreased fibrosis (diaphragm and quadriceps), collagen I and III expression, collagen protein, and smooth muscle actin content after 10 wk treatment. Muscle-cell proliferation increased at 5 wk, and hepatocyte growth factor increased by 10 wk treatment. Halo markedly improved both cardiac and respiratory function and reduced damage and improved recovery from exercise. The overall impact of established dystrophy and dysfunction in cardiac and skeletal muscles was reduced by Halo treatment. Marked improvements in vital-organ functions implicate Halo as a strong candidate drug to reduce morbidity and mortality in Duchenne muscular dystrophy. Copyright © 2008 the American Physiological Society.
Scientific Publication
You may also be interested in